FR2966732A1 - Use of cinnamic acid and its metabolite, salt, inclusion compound or solvate for obtaining a medicament for preventing or treating infections caused by an antigen-resistant or by a combination of antigens e.g. Candida spp. and E.coli - Google Patents
Use of cinnamic acid and its metabolite, salt, inclusion compound or solvate for obtaining a medicament for preventing or treating infections caused by an antigen-resistant or by a combination of antigens e.g. Candida spp. and E.coli Download PDFInfo
- Publication number
- FR2966732A1 FR2966732A1 FR1058971A FR1058971A FR2966732A1 FR 2966732 A1 FR2966732 A1 FR 2966732A1 FR 1058971 A FR1058971 A FR 1058971A FR 1058971 A FR1058971 A FR 1058971A FR 2966732 A1 FR2966732 A1 FR 2966732A1
- Authority
- FR
- France
- Prior art keywords
- spp
- resistant
- coli
- albicans
- aureus
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 title claims abstract description 47
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 title claims abstract description 36
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 title claims abstract description 36
- 229930016911 cinnamic acid Natural products 0.000 title claims abstract description 35
- 235000013985 cinnamic acid Nutrition 0.000 title claims abstract description 35
- 239000000427 antigen Substances 0.000 title claims abstract description 32
- 108091007433 antigens Proteins 0.000 title claims abstract description 32
- 102000036639 antigens Human genes 0.000 title claims abstract description 32
- 208000015181 infectious disease Diseases 0.000 title claims abstract description 21
- 239000003814 drug Substances 0.000 title claims abstract description 12
- 150000003839 salts Chemical class 0.000 title claims abstract description 9
- 239000002207 metabolite Substances 0.000 title claims abstract description 8
- 239000012453 solvate Substances 0.000 title claims abstract description 7
- 150000001875 compounds Chemical class 0.000 title claims abstract description 6
- 241000588724 Escherichia coli Species 0.000 title claims description 31
- 241000250507 Gigaspora candida Species 0.000 title 1
- 230000003110 anti-inflammatory effect Effects 0.000 claims abstract description 3
- KJPRLNWUNMBNBZ-QPJJXVBHSA-N (E)-cinnamaldehyde Chemical compound O=C\C=C\C1=CC=CC=C1 KJPRLNWUNMBNBZ-QPJJXVBHSA-N 0.000 claims description 38
- 241000222122 Candida albicans Species 0.000 claims description 26
- 239000003242 anti bacterial agent Substances 0.000 claims description 21
- 229940088710 antibiotic agent Drugs 0.000 claims description 21
- ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 claims description 16
- -1 aminopenicillins Chemical class 0.000 claims description 14
- 229940121375 antifungal agent Drugs 0.000 claims description 13
- 230000003115 biocidal effect Effects 0.000 claims description 10
- 229960003022 amoxicillin Drugs 0.000 claims description 9
- LSQZJLSUYDQPKJ-NJBDSQKTSA-N amoxicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=C(O)C=C1 LSQZJLSUYDQPKJ-NJBDSQKTSA-N 0.000 claims description 9
- LSQZJLSUYDQPKJ-UHFFFAOYSA-N p-Hydroxyampicillin Natural products O=C1N2C(C(O)=O)C(C)(C)SC2C1NC(=O)C(N)C1=CC=C(O)C=C1 LSQZJLSUYDQPKJ-UHFFFAOYSA-N 0.000 claims description 9
- 239000003443 antiviral agent Substances 0.000 claims description 8
- 229940121357 antivirals Drugs 0.000 claims description 8
- MYSWGUAQZAJSOK-UHFFFAOYSA-N ciprofloxacin Chemical compound C12=CC(N3CCNCC3)=C(F)C=C2C(=O)C(C(=O)O)=CN1C1CC1 MYSWGUAQZAJSOK-UHFFFAOYSA-N 0.000 claims description 8
- 229960003276 erythromycin Drugs 0.000 claims description 8
- UBQKCCHYAOITMY-UHFFFAOYSA-N pyridin-2-ol Chemical class OC1=CC=CC=N1 UBQKCCHYAOITMY-UHFFFAOYSA-N 0.000 claims description 8
- 241000193996 Streptococcus pyogenes Species 0.000 claims description 7
- IECPWNUMDGFDKC-UHFFFAOYSA-N Fusicsaeure Natural products C12C(O)CC3C(=C(CCC=C(C)C)C(O)=O)C(OC(C)=O)CC3(C)C1(C)CCC1C2(C)CCC(O)C1C IECPWNUMDGFDKC-UHFFFAOYSA-N 0.000 claims description 6
- 241000207202 Gardnerella Species 0.000 claims description 6
- 241001480037 Microsporum Species 0.000 claims description 6
- QIAFMBKCNZACKA-UHFFFAOYSA-N N-benzoylglycine Chemical compound OC(=O)CNC(=O)C1=CC=CC=C1 QIAFMBKCNZACKA-UHFFFAOYSA-N 0.000 claims description 6
- 241000186429 Propionibacterium Species 0.000 claims description 6
- 241000223238 Trichophyton Species 0.000 claims description 6
- 229940079593 drug Drugs 0.000 claims description 6
- 229960004675 fusidic acid Drugs 0.000 claims description 6
- IECPWNUMDGFDKC-MZJAQBGESA-N fusidic acid Chemical compound O[C@@H]([C@@H]12)C[C@H]3\C(=C(/CCC=C(C)C)C(O)=O)[C@@H](OC(C)=O)C[C@]3(C)[C@@]2(C)CC[C@@H]2[C@]1(C)CC[C@@H](O)[C@H]2C IECPWNUMDGFDKC-MZJAQBGESA-N 0.000 claims description 6
- 241000894006 Bacteria Species 0.000 claims description 5
- 206010063057 Cystitis noninfective Diseases 0.000 claims description 5
- 201000004624 Dermatitis Diseases 0.000 claims description 5
- 241000233866 Fungi Species 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010046914 Vaginal infection Diseases 0.000 claims description 5
- 201000008100 Vaginitis Diseases 0.000 claims description 5
- 230000001154 acute effect Effects 0.000 claims description 5
- 208000010668 atopic eczema Diseases 0.000 claims description 5
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 5
- 201000003139 chronic cystitis Diseases 0.000 claims description 5
- 241000555676 Malassezia Species 0.000 claims description 4
- 241000589516 Pseudomonas Species 0.000 claims description 4
- 241000191940 Staphylococcus Species 0.000 claims description 4
- 241000191967 Staphylococcus aureus Species 0.000 claims description 4
- 241000194017 Streptococcus Species 0.000 claims description 4
- 229960003405 ciprofloxacin Drugs 0.000 claims description 4
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims description 3
- 241000700605 Viruses Species 0.000 claims description 3
- 230000002421 anti-septic effect Effects 0.000 claims description 3
- 230000002921 anti-spasmodic effect Effects 0.000 claims description 3
- 229940124575 antispasmodic agent Drugs 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 206010022000 influenza Diseases 0.000 claims description 3
- 230000035772 mutation Effects 0.000 claims description 3
- FUBFWTUFPGFHOJ-UHFFFAOYSA-N 2-nitrofuran Chemical class [O-][N+](=O)C1=CC=CO1 FUBFWTUFPGFHOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000005711 Benzoic acid Substances 0.000 claims description 2
- 239000004342 Benzoyl peroxide Substances 0.000 claims description 2
- OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 claims description 2
- 241000222120 Candida <Saccharomycetales> Species 0.000 claims description 2
- GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 claims description 2
- 241000186427 Cutibacterium acnes Species 0.000 claims description 2
- 241000207201 Gardnerella vaginalis Species 0.000 claims description 2
- 241000700588 Human alphaherpesvirus 1 Species 0.000 claims description 2
- 241000701074 Human alphaherpesvirus 2 Species 0.000 claims description 2
- 241000701085 Human alphaherpesvirus 3 Species 0.000 claims description 2
- 241000588748 Klebsiella Species 0.000 claims description 2
- 241000711386 Mumps virus Species 0.000 claims description 2
- 241000606860 Pasteurella Species 0.000 claims description 2
- 229930182555 Penicillin Natural products 0.000 claims description 2
- 241000588769 Proteus <enterobacteria> Species 0.000 claims description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 2
- 229960000723 ampicillin Drugs 0.000 claims description 2
- 239000002260 anti-inflammatory agent Substances 0.000 claims description 2
- 229940121363 anti-inflammatory agent Drugs 0.000 claims description 2
- 235000010233 benzoic acid Nutrition 0.000 claims description 2
- 229960003328 benzoyl peroxide Drugs 0.000 claims description 2
- 235000019400 benzoyl peroxide Nutrition 0.000 claims description 2
- 229940095731 candida albicans Drugs 0.000 claims description 2
- 229960003260 chlorhexidine Drugs 0.000 claims description 2
- 150000002460 imidazoles Chemical class 0.000 claims description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 2
- 229960000282 metronidazole Drugs 0.000 claims description 2
- VAOCPAMSLUNLGC-UHFFFAOYSA-N metronidazole Chemical compound CC1=NC=C([N+]([O-])=O)N1CCO VAOCPAMSLUNLGC-UHFFFAOYSA-N 0.000 claims description 2
- 150000002960 penicillins Chemical class 0.000 claims description 2
- 229940055019 propionibacterium acne Drugs 0.000 claims description 2
- LISFMEBWQUVKPJ-UHFFFAOYSA-N quinolin-2-ol Chemical compound C1=CC=C2NC(=O)C=CC2=C1 LISFMEBWQUVKPJ-UHFFFAOYSA-N 0.000 claims description 2
- 229940124530 sulfonamide Drugs 0.000 claims description 2
- 150000003456 sulfonamides Chemical class 0.000 claims description 2
- 206010041925 Staphylococcal infections Diseases 0.000 claims 1
- 208000015688 methicillin-resistant staphylococcus aureus infectious disease Diseases 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 3
- 230000000844 anti-bacterial effect Effects 0.000 abstract description 2
- 230000002682 anti-psoriatic effect Effects 0.000 abstract 1
- 230000010534 mechanism of action Effects 0.000 abstract 1
- 229940117916 cinnamic aldehyde Drugs 0.000 description 36
- KJPRLNWUNMBNBZ-UHFFFAOYSA-N cinnamic aldehyde Natural products O=CC=CC1=CC=CC=C1 KJPRLNWUNMBNBZ-UHFFFAOYSA-N 0.000 description 36
- 238000011282 treatment Methods 0.000 description 27
- WBYWAXJHAXSJNI-VOTSOKGWSA-N trans-cinnamic acid Chemical compound OC(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-N 0.000 description 12
- 230000001580 bacterial effect Effects 0.000 description 10
- LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 9
- 229960003913 econazole Drugs 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 239000000203 mixture Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 5
- 239000003246 corticosteroid Substances 0.000 description 5
- 229960001334 corticosteroids Drugs 0.000 description 5
- 201000003146 cystitis Diseases 0.000 description 5
- 229960004125 ketoconazole Drugs 0.000 description 5
- 230000000699 topical effect Effects 0.000 description 5
- 208000005615 Interstitial Cystitis Diseases 0.000 description 4
- JPYHHZQJCSQRJY-UHFFFAOYSA-N Phloroglucinol Natural products CCC=CCC=CCC=CCC=CCCCCC(=O)C1=C(O)C=C(O)C=C1O JPYHHZQJCSQRJY-UHFFFAOYSA-N 0.000 description 4
- 201000005661 acute cystitis Diseases 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 206010009887 colitis Diseases 0.000 description 4
- 229960001553 phloroglucinol Drugs 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
- 230000002485 urinary effect Effects 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 206010052428 Wound Diseases 0.000 description 3
- 208000027418 Wounds and injury Diseases 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 244000052616 bacterial pathogen Species 0.000 description 3
- 239000006071 cream Substances 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 3
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 3
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 229960000564 nitrofurantoin Drugs 0.000 description 3
- NXFQHRVNIOXGAQ-YCRREMRBSA-N nitrofurantoin Chemical compound O1C([N+](=O)[O-])=CC=C1\C=N\N1C(=O)NC(=O)C1 NXFQHRVNIOXGAQ-YCRREMRBSA-N 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 235000019198 oils Nutrition 0.000 description 3
- CNXNMLQATFFYLX-ICTDYHGOSA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-1-[(e,2r,5s)-5-cyclopropyl-5-hydroxypent-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol;[2-[(8s,9r,10s,11s,13s,14s,16s,17r)-9-fluoro-11-hydroxy-10,13,16-trime Chemical compound C1([C@H](O)/C=C/[C@@H](C)[C@@H]2[C@]3(CCCC(/[C@@H]3CC2)=C\C=C\2C([C@@H](O)C[C@H](O)C/2)=C)C)CC1.C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CNXNMLQATFFYLX-ICTDYHGOSA-N 0.000 description 2
- YVMBAUWDIGJRNY-BESUKNQGSA-N 4o8o7q7iu4 Chemical compound C1C(=O)C[C@H](O)\C=C(/C)\C=C\CNC(=O)\C=C\[C@@H](C)[C@@H](C(C)C)OC(=O)C2=CCCN2C(=O)C2=COC1=N2.N([C@@H]1C(=O)N[C@@H](C(N2CCC[C@H]2C(=O)N(C)[C@@H](CC=2C=CC(=CC=2)N(C)C)C(=O)N2CCC(=O)C[C@H]2C(=O)N[C@H](C(=O)O[C@@H]1C)C=1C=CC=CC=1)=O)CC)C(=O)C1=NC=CC=C1O YVMBAUWDIGJRNY-BESUKNQGSA-N 0.000 description 2
- 206010007134 Candida infections Diseases 0.000 description 2
- 241000195493 Cryptophyta Species 0.000 description 2
- 208000001840 Dandruff Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 206010017553 Furuncle Diseases 0.000 description 2
- HEFNNWSXXWATRW-UHFFFAOYSA-N Ibuprofen Chemical compound CC(C)CC1=CC=C(C(C)C(O)=O)C=C1 HEFNNWSXXWATRW-UHFFFAOYSA-N 0.000 description 2
- 206010065764 Mucosal infection Diseases 0.000 description 2
- 108010079780 Pristinamycin Proteins 0.000 description 2
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 2
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000000843 anti-fungal effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- CIWBQSYVNNPZIQ-XYWKZLDCSA-N betamethasone dipropionate Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O CIWBQSYVNNPZIQ-XYWKZLDCSA-N 0.000 description 2
- 229960001102 betamethasone dipropionate Drugs 0.000 description 2
- 201000003984 candidiasis Diseases 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003925 fat Substances 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000002169 hydrotherapy Methods 0.000 description 2
- 229960001680 ibuprofen Drugs 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002803 maceration Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- QCDYQQDYXPDABM-UHFFFAOYSA-N phloroglucinol Chemical compound OC1=CC(O)=CC(O)=C1 QCDYQQDYXPDABM-UHFFFAOYSA-N 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 229940112971 protopic Drugs 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 229960004889 salicylic acid Drugs 0.000 description 2
- 239000011669 selenium Substances 0.000 description 2
- 229910052711 selenium Inorganic materials 0.000 description 2
- 201000009890 sinusitis Diseases 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000011200 topical administration Methods 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- YGTUPRIZNBMOFV-UHFFFAOYSA-N 2-(4-hydroxybenzoyl)benzoic acid Chemical compound OC(=O)C1=CC=CC=C1C(=O)C1=CC=C(O)C=C1 YGTUPRIZNBMOFV-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-N 5-oxo-L-proline Chemical compound OC(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- 241000195940 Bryophyta Species 0.000 description 1
- 206010006563 Bullous impetigo Diseases 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- DSLZVSRJTYRBFB-LLEIAEIESA-N D-glucaric acid Chemical compound OC(=O)[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O DSLZVSRJTYRBFB-LLEIAEIESA-N 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-M D-gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C([O-])=O RGHNJXZEOKUKBD-SQOUGZDYSA-M 0.000 description 1
- AEMOLEFTQBMNLQ-AQKNRBDQSA-N D-glucopyranuronic acid Chemical compound OC1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O AEMOLEFTQBMNLQ-AQKNRBDQSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 239000004097 EU approved flavor enhancer Substances 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 206010016936 Folliculitis Diseases 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010018143 Genital candidiasis Diseases 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 208000007514 Herpes zoster Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 206010021531 Impetigo Diseases 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-L Malonate Chemical compound [O-]C(=O)CC([O-])=O OFOBLEOULBTSOW-UHFFFAOYSA-L 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 201000005505 Measles Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 208000005647 Mumps Diseases 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- 241000606856 Pasteurella multocida Species 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241000588770 Proteus mirabilis Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037596 Pyelonephritis Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 229920002253 Tannate Polymers 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 description 1
- 241000287411 Turdidae Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 201000007096 Vulvovaginal Candidiasis Diseases 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- WNLRTRBMVRJNCN-UHFFFAOYSA-L adipate(2-) Chemical compound [O-]C(=O)CCCCC([O-])=O WNLRTRBMVRJNCN-UHFFFAOYSA-L 0.000 description 1
- 241001148470 aerobic bacillus Species 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 201000003465 angular cheilitis Diseases 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- MIOPJNTWMNEORI-UHFFFAOYSA-N camphorsulfonic acid Chemical compound C1CC2(CS(O)(=O)=O)C(=O)CC1C2(C)C MIOPJNTWMNEORI-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 208000007287 cheilitis Diseases 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000008119 colloidal silica Substances 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- SPCNPOWOBZQWJK-UHFFFAOYSA-N dimethoxy-(2-propan-2-ylsulfanylethylsulfanyl)-sulfanylidene-$l^{5}-phosphane Chemical compound COP(=S)(OC)SCCSC(C)C SPCNPOWOBZQWJK-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019264 food flavour enhancer Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229940044170 formate Drugs 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 208000003512 furunculosis Diseases 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 229960001731 gluceptate Drugs 0.000 description 1
- KWMLJOLKUYYJFJ-VFUOTHLCSA-N glucoheptonic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O)C(O)=O KWMLJOLKUYYJFJ-VFUOTHLCSA-N 0.000 description 1
- 229940050410 gluconate Drugs 0.000 description 1
- 229940097042 glucuronate Drugs 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229950000177 hibenzate Drugs 0.000 description 1
- 238000007731 hot pressing Methods 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 239000012678 infectious agent Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- 239000008297 liquid dosage form Substances 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- JZMJDSHXVKJFKW-UHFFFAOYSA-M methyl sulfate(1-) Chemical compound COS([O-])(=O)=O JZMJDSHXVKJFKW-UHFFFAOYSA-M 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 235000011929 mousse Nutrition 0.000 description 1
- 208000010805 mumps infectious disease Diseases 0.000 description 1
- 125000005487 naphthalate group Chemical group 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- 229940042126 oral powder Drugs 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- PXQPEWDEAKTCGB-UHFFFAOYSA-N orotic acid Chemical compound OC(=O)C1=CC(=O)NC(=O)N1 PXQPEWDEAKTCGB-UHFFFAOYSA-N 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- 229940051027 pasteurella multocida Drugs 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 238000003825 pressing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 201000007094 prostatitis Diseases 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 229940043131 pyroglutamate Drugs 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007886 soft shell capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 150000003890 succinate salts Chemical group 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 229910021653 sulphate ion Inorganic materials 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229940098465 tincture Drugs 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 210000000626 ureter Anatomy 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 208000000143 urethritis Diseases 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 208000019206 urinary tract infection Diseases 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 238000009834 vaporization Methods 0.000 description 1
- 230000008016 vaporization Effects 0.000 description 1
- 239000002966 varnish Substances 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
1 UTILISATION DE L'ACIDE CINNAMIQUE POUR PREVENIR OU TRAITER DES INFECTIONS PROVOQUEES PAR UN ANTIGENE RESISTANT OU UNE COMBINAISON D'ANTIGENES La présente invention concerne l'utilisation de l'acide cinnamique pour prévenir ou traiter des infections provoquées par un antigène résistant ou une combinaison d'antigènes. The present invention relates to the use of cinnamic acid for preventing or treating infections caused by a resistant antigen or a combination thereof. BACKGROUND OF THE INVENTION The present invention relates to the use of cinnamic acid to prevent or treat infections caused by a resistant antigen or a combination thereof. antigen.
De nos jours, l'acide cinnamique est une molécule qui est largement utilisée dans divers domaines. En effet, on peut trouver l'acide cinnamique dans l'industrie du parfum ; il sert également pour la composition d'exhausteurs de goût. Nowadays, cinnamic acid is a molecule that is widely used in various fields. Indeed, cinnamic acid can be found in the perfume industry; it is also used for the composition of flavor enhancers.
Par ailleurs, il est connu depuis fort longtemps que l'acide cinnamique possède des propriétés antiseptique et antifongique. De ce fait, on le trouve également dans certains produits pharmaceutiques. Actuellement, de nombreux antigènes sont traités par l'utilisation d'antibiotiques. Cependant, l'utilisation massive de ces derniers par l'homme a entraîné la résistance de certains d'entre eux vis-à-vis des antibiotiques. En effet, les antibiotiques exercent une pression sélective très forte et éliminent les antigènes sensibles mais les antigènes présentant une mutation leur permettant d'y survivre continuent quant à eux à se reproduire, en transmettant à leur descendance leurs gènes de résistance, produisant rapidement une génération d'antigènes pleinement ou majoritairement résistants. Il est à noter que ce phénomène de résistance n'est pas propre aux antibiotiques mais existe également pour d'autres familles de molécules telles que les antifongiques, les corticoïdes ou les antiviraux. 2 De plus, lorsque les antigènes se trouvent sous forme combinée, ces derniers perdent leur individualité. Par conséquent, dans ce cas, les antibiotiques soit ne s'avèrent pas être efficaces ou bien lorsqu'ils sont efficaces, la co-prescription d'une autre famille d'antibiotique doit être administrée au patient. Il en est de même pour les antifongiques, les corticoïdes et les antiviraux. La résistance des germes conduit donc soit à une augmentation de la durée du traitement ou à la nécessité d'associer plusieurs familles de molécules simultanément, et d'en augmenter le dosage. Il serait donc très avantageux de trouver un palliatif aux antibiotiques, antifongiques, corticoïdes et antiviraux 15 classiquement utilisés. Or, la Demanderesse a trouvé de façon surprenante que l'utilisation d'acide cinnamique permettait de répondre à cette problématique en étant efficace, à des doses raisonnables, sur des antigènes combinés ou des antigènes 20 résistants. De plus, l'utilisation d'acide cinnamique peut être associée à une autre substance active pour compléter son action sans augmenter sa durée de traitement. Par ailleurs, la petite taille de la molécule d'acide 25 cinnamique présente un avantage non négligeable vis-à-vis des antibiotiques ou des antifongiques lui permettant de passer plus facilement à travers les cellules. De ce fait, l'acide cinnamique s'avère être plus efficace que les antibiotiques ou antifongiques classiquement utilisés sur 30 certains antigènes résistants. L'objet de la présente invention est donc l'utilisation d'acide cinnamique, de ses métabolites, ses sels, ses composés d'inclusions et ses solvates pour l'obtention d'un médicament destiné à prévenir ou traiter 3 des infections provoquées par un antigène résistant ou par une combinaison d'antigènes dont l'un au moins peut être résistant. Dans la présente demande, on entend par "antigène" la désignation soit d'une bactérie, d'une levure, d'un champignon, d'un germe ou d'un virus. En l'absence d'indication spécifique, dans la présente invention, le terme "acide cinnamique" couvre l'acide cinnamique lui-même, ses différentes formes isomériques, ses métabolites, ses sels, ses composés d'inclusions et ses solvates. On utilisera indifféremment le terme d'"acide cinnamique" ou de "cinnamaldéhyde". Par "antigène résistant", on entend un antigène présentant des résistances au traitement qui lui est spécifique (antibiotiques, antifongiques, corticoïdes et antiviraux). Par combinaison d'antigènes, on entend l'association d'au moins deux antigènes de même nature ou de nature différente. Furthermore, it has long been known that cinnamic acid has antiseptic and antifungal properties. As a result, it is also found in certain pharmaceutical products. Currently, many antigens are treated by the use of antibiotics. However, the massive use of these by humans has led to the resistance of some of them to antibiotics. In fact, antibiotics exert a very strong selective pressure and eliminate the sensitive antigens, but the antigens with a mutation allowing them to survive continue to reproduce themselves, by transmitting to their offspring their resistance genes, producing rapidly a generation. antigens fully or predominantly resistant. It should be noted that this phenomenon of resistance is not specific to antibiotics but also exists for other families of molecules such as antifungals, corticosteroids or antivirals. In addition, when the antigens are in combined form, the latter lose their individuality. Therefore, in this case, the antibiotics either do not prove to be effective or when they are effective, the co-prescription of another family of antibiotics must be administered to the patient. The same is true for antifungals, corticosteroids and antivirals. The resistance of the germs therefore leads either to an increase in the duration of the treatment or the need to combine several families of molecules simultaneously, and to increase the dosage. It would therefore be very advantageous to find a palliative antibiotic, antifungal, steroids and antiviral 15 classically used. Now, the Applicant has surprisingly found that the use of cinnamic acid makes it possible to respond to this problem by being effective, at reasonable doses, on combined antigens or resistant antigens. In addition, the use of cinnamic acid may be associated with another active substance to complete its action without increasing its duration of treatment. Furthermore, the small size of the cinnamic acid molecule has a significant advantage over antibiotics or antifungals allowing it to pass more easily through the cells. As a result, cinnamic acid is found to be more effective than the antibiotics or antifungals conventionally used on certain resistant antigens. The object of the present invention is therefore the use of cinnamic acid, its metabolites, its salts, its inclusion compounds and its solvates in order to obtain a medicament intended to prevent or treat infections caused by a resistant antigen or a combination of antigens at least one of which may be resistant. In the present application, the term "antigen" means the designation of a bacterium, a yeast, a fungus, a germ or a virus. In the absence of specific indication, in the present invention, the term "cinnamic acid" covers cinnamic acid itself, its various isomeric forms, its metabolites, its salts, its inclusion compounds and its solvates. The term "cinnamic acid" or "cinnamaldehyde" is used interchangeably. By "resistant antigen" is meant an antigen presenting resistance to the treatment specific to it (antibiotics, antifungals, corticosteroids and antivirals). By combination of antigens is meant the combination of at least two antigens of the same or different nature.
Les antigènes résistants qui peuvent être traités conformément à l'invention sont choisis dans le groupe comprenant des bactéries telles que Escherichia coli antibiorésistant, Staphylococcus aureus résistant à l'acide fusidique, l'érythromycine et aux pyridones, Staphylococcus Aureus Resistant Methyl (SARM), Streptococcus pyogenes résistant aux antibiotiques et particulièrement à l'érythromycine et ciprofloxacine et aux pyridones, S. pyogenes antibiorésistant, Gardnerella vaginalis résistante aux antibiotiques et particulièrement au métronidazole et à l'acide fusidique, propionibacterium acnes résistant aux antibiotiques et antiseptique, tout particulièrement à l'érythromycine, l'acide fusidique, le peroxyde de benzoyle et la chloréxidine et aux pyridones, pneumocoques résistants aux antibiotiques et particulièrement aux 4 pénicillines, à l'ampicilline, l'amoxicilline et l'érythromycine; des levures ou champignons tels que Candida albicans résistant aux quinolones, imidazolés, pyridones, aminopénicillines, nitrofuranes et sulfamides; et des virus tels que l'haemophillus influenza type A, paramixoviridae, le virus ourlien, le VZV ou herpès simplex type 1, 2 et 3, ces virus ayant subi des mutations. Parmi les combinaisons d'antigènes connues, on peut citer E.coli & Proteus spp, E.coli et Klebsiella spp, E.coli et Pseudomonas spp, E.coli et Pasteurella spp, E.coli et Staphylococcus spp, E.coli et Candida spp, E.coli et Trichophyton spp, E.coli et Microsporum spp, E.coli et Epidemophyton spp, E.coli et Gardnerella spp, E.coli et Propionibacterium spp, E.coli et Pneumococcus spp, C.albicans et Staphylococcus spp, C.albicans et Pseudomonas spp, C.albicans et Streptococcus spp, C.albicans et Propionibacterium spp, C.albicans et Trichophyton spp, C.albicans et Microsporum spp, C.albicans et Epidemophyton spp, C.albicans et Malassezia spp, C.albicans et Gardnerella spp, C.albicans et Pneumococcus spp, S.aureus et Streptococcus spp, S.aureus et Trichophyton, S.aureus et Microsporum spp, S.aureus et Epidemophyton spp, S.aureus et Gardnerella spp, S.aureus et Propionibacterium spp, S.aureus et Malassezia spp, S.aureus et Pneumococcus spp. Resistant antigens that can be treated according to the invention are selected from the group consisting of bacteria such as antibiotic-resistant Escherichia coli, fusidic acid resistant Staphylococcus aureus, erythromycin and pyridones, Staphylococcus Aureus Resistant Methyl (SARM), Streptococcus pyogenes resistant to antibiotics and particularly to erythromycin and ciprofloxacin and pyridones, antibiotic-resistant S. pyogenes, Gardnerella vaginalis resistant to antibiotics and particularly to metronidazole and fusidic acid, antibiotic-resistant propionibacterium acnes and antiseptic, especially erythromycin, fusidic acid, benzoyl peroxide and chlorhexidine and pyridones, pneumococci resistant to antibiotics and especially to penicillins, ampicillin, amoxicillin and erythromycin; yeasts or fungi such as quinolone-resistant Candida albicans, imidazoles, pyridones, aminopenicillins, nitrofurans and sulfonamides; and viruses such as haemophillus influenza type A, paramixoviridae, mumps virus, VZV or herpes simplex type 1, 2 and 3, which have undergone mutations. Among the known combinations of antigens, mention may be made of E. coli & Proteus spp., E. coli and Klebsiella spp., E. coli and Pseudomonas spp., E. coli and Pasteurella spp., E. coli and Staphylococcus spp. Candida spp., E. coli and Trichophyton spp., E. coli and Microsporum spp., E. coli and Epidemophyton spp., E.coli and Gardnerella spp., E. coli and Propionibacterium spp., E. coli and Pneumococcus spp., C.albicans and Staphylococcus spp. spp, C.albicans and Pseudomonas spp., C.albicans and Streptococcus spp., C.albicans and Propionibacterium spp., C.albicans and Trichophyton spp., C.albicans and Microsporum spp., C.albicans and Epidemophyton spp., C.albicans and Malassezia spp. , C.albicans and Gardnerella spp, C.albicans and Pneumococcus spp, S.aureus and Streptococcus spp, S.aureus and Trichophyton, S.aureus and Microsporum spp, S.aureus and Epidemophyton spp, S.aureus and Gardnerella spp, S .aureus and Propionibacterium spp, S.aureus and Malassezia spp, S.aureus and Pneumococcus spp.
Selon un mode préféré de l'invention, l'acide cinnamique permet de traiter les pathologies provoquées par la combinaison d'au moins deux des antigènes choisis dans le groupe comprenant Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa et Pasteurella multocida. Selon l'invention, l'acide cinnamique utilisé peut se trouver sous forme de mélange racémique, c'est-à-dire présentant une quantité égale d'acide trans-cinnamique et d'acide cis-cinnamique, ou bien il peut se présenter sous la forme d'un mélange non racémique. Selon un mode de réalisation préféré de l'invention, l'acide cinnamique utilisé se trouve sous sa forme d'acide 5 trans-cinnamique à plus de 90%, de préférence à plus de 95% et plus préférentiellement encore à plus de 98%. Selon un autre mode de réalisation, l'acide cinnamique peut se trouver sous forme de sels, de solvates ou bien former des composés d'inclusion avec par exemple des cyclodextrines. A titre d'exemples de sels possibles, on peut citer l'acétate, adipate, aspartate, benzoate, bésylate, bicarbonate, carbonate, bisulfate, sulfate, borate, camsylate, citrate, cyclamate, édisylate, ésylate, formiate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate,hibenzate, chlorure, chlorhydrate, bromure, bromhydrate, iodure, iodhydrate, isothionate, lactate, malate, maléate, malonate, mésylate, méthylsulfate, naphtylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate,bphosphate/hydrogeno-phosphate/dihydrogenophosphate, pyroglutamate, saccharate, stéarate, succinate, tannate, tartrate, tosylate, trifluoroacétate et xinofoate, de préférence le sel est le succinate. According to a preferred mode of the invention, cinnamic acid makes it possible to treat pathologies caused by the combination of at least two of the antigens chosen from the group comprising Escherichia coli, Proteus mirabilis, Klebsiella pneumoniae, Pseudomonas aeruginosa and Pasteurella multocida. According to the invention, the cinnamic acid used can be in the form of a racemic mixture, that is to say having an equal amount of trans-cinnamic acid and cis-cinnamic acid, or it can occur in the form of a non-racemic mixture. According to a preferred embodiment of the invention, the cinnamic acid used is in the form of trans-cinnamic acid at more than 90%, preferably at more than 95% and more preferably at more than 98%. . According to another embodiment, the cinnamic acid may be in the form of salts, solvates or may form inclusion compounds with for example cyclodextrins. By way of examples of possible salts, mention may be made of acetate, adipate, aspartate, benzoate, besylate, bicarbonate, carbonate, bisulfate, sulphate, borate, camsylate, citrate, cyclamate, edisylate, esylate, formate, fumarate, gluceptate, gluconate, glucuronate, hexafluorophosphate, hibenzate, chloride, hydrochloride, bromide, hydrobromide, iodide, iodohydrate, isothionate, lactate, malate, maleate, malonate, mesylate, methylsulfate, naphthylate, 2-napsylate, nicotinate, nitrate, orotate, oxalate, palmitate, pamoate, bphosphate / hydrogen phosphate / dihydrogen phosphate, pyroglutamate, saccharate, stearate, succinate, tannate, tartrate, tosylate, trifluoroacetate and xinofoate, preferably the salt is succinate.
Le terme solvate est utilisé ici pour décrire un complexe moléculaire comprenant l'acide cinnamique et au moins une molécule solvant pharmaceutiquement acceptable, par exemple l'eau ou l'éthanol. Selon l'invention, le médicament peut être administré par voie orale, trans-cutanée, trans-cutanéomuqueuse ou topique, la voie orale incluant la voie aérienne par masque ou brumisation est incluse dans la voie orale. Selon un mode de réalisation préféré de l'invention, la voie d'administration privilégiée est la voie orale. 6 La voie topique a une action par la molécule mère uniquement. En revanche, les voies orales et trans cutanéomuqueuses ont une métabolisation de la molécule mère en 2 métabolites essentiels (acide hippurique et benzoïque) retrouvés essentiellement dans les urines à 93% créant ainsi un milieu non favorable à la prolifération de germes. Ces métabolites sont donc actifs tous les deux vis-à-vis des infections de l'arbre urinaire. Par arbre urinaire, on entend l'ensemble constitué par les reins, l'uretère (droite et gauche), la vessie et l'urètre. De façon surprenante, les inventeurs ont trouvé que les métabolites acides hippurique et benzoïque ont une activité également par voie topique sur les germes résistants. The term solvate is used herein to describe a molecular complex comprising cinnamic acid and at least one pharmaceutically acceptable solvent molecule, for example water or ethanol. According to the invention, the medicament can be administered orally, transcutaneously, transcutaneousomucous or topical, the oral route including the airway mask or mist is included in the oral route. According to a preferred embodiment of the invention, the preferred route of administration is the oral route. 6 The topical route has an action by the parent molecule only. On the other hand, the oral and trans-cutaneous and mucosal routes metabolize the parent molecule into 2 essential metabolites (hippuric and benzoic acid) found mainly in the urine at 93%, thus creating a medium that is not conducive to the proliferation of germs. These metabolites are therefore both active against infections of the urinary shaft. Urinary tree is the group consisting of the kidneys, the ureter (right and left), the bladder and the urethra. Surprisingly, the inventors have found that the hippuric and benzoic acid metabolites have an activity also topically on the resistant germs.
Les formes galéniques seront choisies selon les pathologies à traiter, et les voies d'administration choisies. A titre d'exemple on peut citer notamment des formes solides, semi-solides, souples, liquides, vaporisées ou pressurisées, vaporisations et diffusions ultrasoniques. The galenic forms will be chosen according to the pathologies to be treated and the routes of administration chosen. By way of example, mention may be made especially of solid, semi-solid, flexible, liquid, vaporized or pressurized forms, vaporizations and ultrasonic diffusions.
Parmi les formes galéniques solides, on peut citer les présentations sous forme de bâton, cachet, comprimé, enrobé ou non, effervescent, soluble, orodispersible, pelliculé, gastrorésistant ou à libération modifiée, capsule à enveloppe molle, dragée, gélule (capsules à enveloppe dure: HPMC, algues, cartilage, os) pelliculée ou non, gastrorésistante ou non, gomme ou pâte à mâcher, granule, granulé, pilule, pastille, poudre orale ou pour application topique, poudre lyophilisée soluble dans un liquide chaud ou froid, tablette, suppositoire ou ovule. Parmi les formes galéniques souples, on peut citer les dispositifs transdermiques, de vernis souples, de tissus imprégnés. Parmi les formes galéniques semi-solides, on peut citer le cataplasme, crème, emplâtres médicamenteux, gel, émulsion, pâte, huile ou pommade. Parmi les formes galéniques 7 liquides, on peut citer les formulations sous forme d'émulsion buvable, de suspension buvable, d'huiles de macération, de teinture officinale, de teinture mère, d'huile végétale en topique, liniment, liquide oral, lotion, mousse, sirop. Parmi les formes galéniques pressurisées ou pneumatiques, on peut citer les formulations sous forme de nébuliseur, inhalateur (par exemple pressurisé à valve doseuse ou à poudre) et diffuseur sonique. Among the solid dosage forms, mention may be made of stick, cachet, tablet, coated or uncoated, effervescent, soluble, orodispersible, film-coated, gastroresistant or modified-release forms, soft-shell capsule, dragee, capsule (capsule-type capsules hard: HPMC, algae, cartilage, bone) film-coated or not, gastroresistant or not, gum or chewing paste, granule, granule, pill, lozenge, oral powder or for topical application, freeze-dried powder soluble in hot or cold liquid, tablet , suppository or ovum. Among the flexible dosage forms include transdermal devices, soft varnishes, impregnated fabrics. Among the semi-solid dosage forms, mention may be made of poultice, cream, medicated plasters, gel, emulsion, paste, oil or ointment. Among the liquid dosage forms, mention may be made of formulations in the form of an oral emulsion, oral suspension, maceration oils, officinal dye, mother tincture, topical vegetable oil, liniment, oral liquid, lotion , mousse, syrup. Among the pressurized or pneumatic dosage forms, there may be mentioned formulations in the form of a nebulizer, an inhaler (for example pressurized with a metering or powder valve) and a sonic diffuser.
Selon la forme galénique utilisée, différents excipients ou véhicules acceptables sur le plan physiologique, essentiellement inertes, peuvent être présents, comme des solutions isotoniques, tamponnées, salines, des sels, gommes, sucres, agents stabilisants, épaississants, édulcorants, gélifiants, tensio-actifs, etc. Dans le cas de gélules ou capsules, on utilise typiquement du stéarate de magnésium et/ou de la silice colloïdale et/ou de la maltodextrine ou de la silice organique ou diverses huiles de macération ou d'expression obtenues par pressage à froid ou à chaud. Par ailleurs, l'enveloppe de ces capsules ou gélules peut être constituée de gélatine d'origine animale, végétale ou de poisson, d'algues, d'hydroxypropyl méthylcellulose (HPMC) et de cellulose. Elles peuvent être revêtues d'une couche gastrorésistante ou non et être modifiées pour effectuer une libération prolongée dans le tractus digestif. Selon l'invention, la concentration en acide cinnamique dans le médicament diffère en fonction du mode d'administration. Depending on the dosage form used, different excipients or physiologically acceptable carriers, essentially inert, may be present, such as isotonic, buffered, saline solutions, salts, gums, sugars, stabilizing agents, thickeners, sweeteners, gelling agents, surfactants, and the like. assets, etc. In the case of capsules or capsules, there is typically used magnesium stearate and / or colloidal silica and / or maltodextrin or organic silica or various maceration or expression oils obtained by cold pressing or hot pressing . Furthermore, the envelope of these capsules or capsules may consist of gelatin of animal, vegetable or fish, algae, hydroxypropyl methylcellulose (HPMC) and cellulose. They may be coated with a gastroresistant layer or not and be modified to perform a sustained release in the digestive tract. According to the invention, the cinnamic acid concentration in the drug differs depending on the mode of administration.
En effet, dans le cas d'une administration par voie orale ou transcutanéo-muqueuse, la concentration de l'acide cinnamique à titre de principe actif dans le médicament est comprise entre 0,03g et 40g/jour, de préférence entre 0,1g 8 et 18g/jour et plus préférentiellement encore entre 0,4g et 7,2g/jour. Dans le cas d'une administration par voie topique, la concentration de l'acide cinnamique à titre de principe actif dans le médicament est comprise entre 0,01g et 25g/jour, de préférence entre 0,1g et 16g/jour et plus préférentiellement encore 0,3g et 10g/jour. Selon l'invention, les infections à prévenir ou à traiter sont des infections en urologie, gynécologie, dermatologie, ORL, pneumologie, gastroentérologie et allergologie. Parmi les pathologies cibles essentielles, on peut citer les infections cutanéo-muqueuses bactériennes telles que l'impétigo, l'impétigo bulleux, la folliculite, le furoncle et la furonculose, l'anthrax, l'érysipèle, les plaies simples, infectées et surinfectées, cystite aiguë, chronique ou interstitielle, les urétrites, les néphrites et pyélonéphrites, les prostatites, les vaginites et les vaginotes ; les infections cutanéo-muqueuses bactériennes et mycosique telles que la perlèche, la glossite, la stomatite, le muguet, la candidose anorectale, les candidoses génitales. On peut également citer les infections cutanéo-muqueuses pulmonaires telles que la grippe, la bronchite, la pneumonie ; les infections cutanéo-muqueuses d'origine virale tels que l'herpès digital, buccal, anorectal et vaginal ; les infections cutanée d'origine virale tels que la rougeole, les oreillons, la varicelle, le zona. Selon un mode de réalisation particulier et pour une administration par voie orale ou injectable, l'invention porte sur l'utilisation d'acide cinnamique pour traiter des infections de l'appareil urinaire, des voies basses ou hautes, et notamment de la cystite, en particulier de la cystite aigue, chronique ou interstitielle. 9 Dans ce mode de réalisation et dans le cas d'une administration par voie orale, la concentration de l'acide cinnamique à titre de principe actif dans le médicament est comprise entre 0,03g et 40g/jour, de préférence entre 0,1g et 18g/jour et plus préférentiellement encore entre 0,4g et 7,2g/jour et dans le cas d'une administration par voie injectable la concentration de l'acide cinnamique à titre de principe actif dans le médicament est comprise entre 0,001g et 5g/jour, de préférence entre 0,01g et 3,5g/jour et plus préférentiellement encore entre 0,01g et 2g/jour De façon préférée, ce médicament destiné au traitement de la cystite aigue, chronique ou interstitielle comprend du transcinnamaldéhyde en tant que principe actif. Selon un autre mode de réalisation, et pour une administration par voie trans-cutanéomuqueuse, l'invention porte sur l'utilisation d'acide cinnamique pour prévenir ou traiter des infections génitales telles que la vaginite ou la vaginose. Selon un autre mode de réalisation particulier et pour une administration par voie topique, l'invention porte sur l'utilisation d'acide cinnamique pour prévenir ou traiter des infections dermatologiques telles que le psoriasis ou l'eczéma. L'utilisation selon l'invention peut être faite seule, en traitement de première intention, ou en combinaison ou alternance avec d'autres traitements, notamment avec les antibiotiques, antifongiques, corticoïdes ou antispasmodiques. Elle permet de réduire la sévérité de l'infection, de bloquer son développement ou de la supprimer totalement. Elle permet de faciliter la défense de l'organisme contre l'infection. Elle est utilisable chez l'humain, mais également chez tout mammifère. Ainsi, selon un autre mode de réalisation, l'invention porte sur l'utilisation d'acide cinnamique en combinaison 10 avec au moins un autre agent thérapeutiquement efficace pour prévenir ou traiter les infections urinaires telles que les cystites aigue, chronique ou interstitielle ou pour traiter les infections dermatologiques telles que le psoriasis ou l'eczéma. Un tel agent thérapeutiquement efficace pouvant être utilisé en association avec l'acide cinnamique est choisi dans le groupe comprenant les antibiotiques, les antifongiques, les antiviraux, les antispasmodiques, les anti-inflammatoires, et leurs mélanges. Parmi les combinaisons possibles, on peut trouver le cinnamaldéhyde et amoxicilline +/- phloroglucinol, cinnamaldéhyde et ciprofloxacine pour le traitement de l'arbre urinaire, ou le cinnamaldéhyde et amoxicilline pour le traitement de la colite bactérienne, ou le cinnamaldéhyde et diprosone, cinnamaldehyde et protopic pour le traitement de l'eczéma, ou le cinnamaldéhyde en solution H/E ou E/H et hydrothérapie riche en sélénium, cinnamaldéhyde et daivobet, le cinnamaldéhyde et acide salicylique + corps gras pour le traitement du psoriasis, ou le cinnamaldéhyde et kétoconazole / éconazole pour le traitement des états pelliculaires ; ou le cinnamaldehyde et ibuprofène pour le traitement des sinusites, ou le cinnamaldéhyde et phloroglucinol pour le traitement des colites spasmodiques ; ou le cinnamaldéhyde et pyostacine pour le traitement des plaies infectées ; ou le cinnamaldéhyde et monazole , cinnamaldéhyde et éconazole pour le traitement des vaginotes, ou cinnamaldehyde et polyginax, cinnamaldehyde et monazole / éconazole pour le traitement des vaginites infectieuses. De façon particulière, on peut utiliser les combinaisons suivantes: - voie orale : o Traitement de l'arbre urinaire, en gélule 5 10 15 20 25 30 cinnamaldéhyde et amoxicilline +/-phloroglucinol cinnamaldéhyde et ciprofloxacine o traitement de la colite bactérienne, en gélule gastrorésistante cinnamaldéhyde et amoxicilline/ - voie topique : o traitement de l'eczéma, en crème hydratante cinnamaldéhyde et diprosone cinnamaldehyde et protopic o traitement du psoriasis, en crème cinnamaldéhyde en solution H/E ou E/H et hydrothérapie riche en sélénium cinnamaldéhyde et daivobet cinnamaldéhyde et acide salicylique + corps gras o traitement des états pelliculaires, en shampoing cinnamaldéhyde et kétoconazole / éconazole o traitement des sinusites cinnamaldehyde et ibuprofène o traitement des colites spasmodiques cinnamaldéhyde et phloroglucinol o traitement des brûlures du 1° et 2° degré infectées, en onction : cinnamaldéhyde et o traitement des plaies infectées, en pommade cinnamaldéhyde et pyostacine - voie vaginale o traitement des vaginotes, en ovule cinnamaldéhyde et monazole cinnamaldéhyde et éconazole o traitement des vaginites infectieuses, en ovule cinnamaldehyde et polyginax 12 cinnamaldehyde et monazole / éconazole Indeed, in the case of oral or transcutaneous-mucous administration, the concentration of cinnamic acid as active principle in the drug is between 0.03g and 40g / day, preferably between 0.1g 8 and 18 g / day and more preferably still between 0.4 g and 7.2 g / day. In the case of a topical administration, the concentration of cinnamic acid as active principle in the drug is between 0.01g and 25g / day, preferably between 0.1g and 16g / day and more preferably still 0.3g and 10g / day. According to the invention, the infections to be prevented or treated are infections in urology, gynecology, dermatology, ENT, pneumology, gastroenterology and allergology. Essential target diseases include bacterial cutaneous and mucosal infections such as impetigo, bullous impetigo, folliculitis, furuncle and furunculosis, anthrax, erysipelas, simple, infected and superinfected wounds. , acute, chronic or interstitial cystitis, urethritis, nephritis and pyelonephritis, prostatitis, vaginitis and vaginosis; bacterial and mycotic skin and mucocutaneous infections such as perleche, glossitis, stomatitis, thrush, anorectal candidiasis, genital candidiasis. It may also be mentioned lung mucosal infections such as influenza, bronchitis, pneumonia; mucocutaneous infections of viral origin such as digital, oral, anorectal and vaginal herpes; skin infections of viral origin such as measles, mumps, chickenpox, shingles. According to a particular embodiment and for oral or injectable administration, the invention relates to the use of cinnamic acid to treat infections of the urinary tract, low or high pathways, and in particular cystitis, especially acute, chronic or interstitial cystitis. In this embodiment and in the case of oral administration, the concentration of cinnamic acid as active ingredient in the drug is between 0.03g and 40g / day, preferably between 0.1g and 18 g / day and even more preferably between 0.4 g and 7.2 g / day and in the case of administration by injection the concentration of cinnamic acid as active ingredient in the drug is between 0.001 g and 5 g / day, preferably between 0.01 g and 3.5 g / day and still more preferably between 0.01 g and 2 g / day. Preferably, this medicament for the treatment of acute, chronic or interstitial cystitis comprises transcinnamaldehyde as as active ingredient. According to another embodiment, and for trans-cutaneous-mucous administration, the invention relates to the use of cinnamic acid to prevent or treat genital infections such as vaginitis or vaginosis. According to another particular embodiment and for topical administration, the invention relates to the use of cinnamic acid to prevent or treat dermatological infections such as psoriasis or eczema. The use according to the invention may be made alone, as a first-line treatment, or in combination or alternation with other treatments, in particular with antibiotics, antifungals, corticosteroids or antispasmodics. It can reduce the severity of the infection, block its development or remove it completely. It helps to facilitate the defense of the body against infection. It can be used in humans, but also in any mammal. Thus, according to another embodiment, the invention relates to the use of cinnamic acid in combination with at least one other therapeutically effective agent for preventing or treating urinary infections such as acute, chronic or interstitial cystitis or for treat dermatological infections such as psoriasis or eczema. Such a therapeutically effective agent that can be used in combination with cinnamic acid is selected from the group consisting of antibiotics, antifungals, antivirals, antispasmodics, anti-inflammatories, and mixtures thereof. Among the possible combinations are cinnamaldehyde and amoxicillin +/- phloroglucinol, cinnamaldehyde and ciprofloxacin for the treatment of the urinary shaft, or cinnamaldehyde and amoxicillin for the treatment of bacterial colitis, or cinnamaldehyde and diprosone, cinnamaldehyde and protopic for the treatment of eczema, or cinnamaldehyde in O / W or W / H solution and selenium-rich hydrotherapy, cinnamaldehyde and daivobet, cinnamaldehyde and salicylic acid + fat for the treatment of psoriasis, or cinnamaldehyde and ketoconazole / econazole for the treatment of dandruff conditions; or cinnamaldehyde and ibuprofen for the treatment of sinusitis, or cinnamaldehyde and phloroglucinol for the treatment of spasmodic colitis; or cinnamaldehyde and pyostacine for the treatment of infected wounds; or cinnamaldehyde and monazole, cinnamaldehyde and econazole for the treatment of vaginotes, or cinnamaldehyde and polyginax, cinnamaldehyde and monazole / econazole for the treatment of infectious vaginitis. In particular, the following combinations can be used: - oral: o Treatment of the urinary tree, in capsule 5 cinnamaldehyde and amoxicillin +/- phloroglucinol cinnamaldehyde and ciprofloxacin o treatment of bacterial colitis, in capsule gastroresistant cinnamaldehyde and amoxicillin / - topical: o treatment of eczema, in moisturizing cream cinnamaldehyde and diprosone cinnamaldehyde and protopic o treatment of psoriasis, cinnamaldehyde cream in solution O / W or W / H and hydrotherapy rich in selenium cinnamaldehyde and daivobet cinnamaldehyde and salicylic acid + oily fats o treatment of dandruff states, shampoo cinnamaldehyde and ketoconazole / econazole o treatment of sinusitis cinnamaldehyde and ibuprofen o treatment of spasmodic colitis cinnamaldehyde and phloroglucinol o treatment of burns of 1 ° and 2 ° degree infected, anointed : cinnamaldehyde and o treatment of infected wounds, in cinnamaldehyde and pyostacine ointment - vaginal route o treatment of vaginotes, in cinnamaldehyde ovule and monazole cinnamaldehyde and econazole o treatment of infectious vaginitis, in cinnamaldehyde ovule and polyginax 12 cinnamaldehyde and monazole / econazole
D'autres aspects et avantages de la présente invention apparaîtront à la lecture des exemples qui suivent, qui doivent être considérés comme illustratifs et non limitatifs. La présente invention sera illustrée par les exemples suivants, qui sont donnés à titre d'illustration uniquement. Other aspects and advantages of the present invention will appear on reading the examples which follow, which should be considered as illustrative and not limiting. The present invention will be illustrated by the following examples, which are given by way of illustration only.
Etude de la comparaison de l'activité entre l'acide cinnamique et des antifongiques, antiviraux et antibiotiques contre des antigènes résistants Study of the comparison of activity between cinnamic acid and antifungals, antivirals and antibiotics against resistant antigens
Objectif et principe de l'étude Déterminer la CMI (Concentration Minimale Inhibitrice) d'acide cinnamique; versus antibiotiques, antifongiques et antiviraux vis-à-vis d'antigènes résistants et/ou de combinaison d'antigènes. Méthodologie et protocole standardisé La méthode est basée sur la détermination de la capacité de micro-organismes à produire une croissance visible dans un bouillon contenant des dilutions en série de l'agent antimicrobien. Des contrôles qualité sont réalisés sur au minimum deux souches bactériennes de référence parmi les 6 souches proposées dans la norme, et ces deux souches sont testées dans les mêmes conditions que les solutions bactériennes testées. L'acide transcinnamique est obtenu par synthèse chimique. La détermination de la CMI de l'acide transcinnamique est réalisée par microdilution en bouillon, conformément à 13 la norme internationale NF EN ISO 20776-1 (Avril 2007) . Systèmes d'essais en laboratoire et de diagnostic in vitro Sensibilité in vitro des agents infectieux et évaluation des performances des dispositifs pour antibiogrammes - Partie 1 : Méthode de référence pour la détermination de la sensibilité in vitro aux agents antimicrobiens des bactéries aérobies à croissance rapide impliquées dans les maladies infectieuses. L'ensemble des manipulations et préparations, est réalisé sous le poste de sécurité microbiologique, dans des conditions stériles. La préparation de l'acide transcinnamique est réalisée dans de l'eau physiologique additionnée de Tween 20 0.5%(v/v) afin de faciliter la solubilisation. La préparation des solutions antibiotiques est réalisée avec les mêmes solutions que celles utilisées pour l'acide transcinnamique. Les plaques de microdilution préparées pour les essais, les témoins des essais, les témoins de croissance positifs et les témoins de croissance négatifs, doivent être inoculées dans les 30 minutes suivant la normalisation (10 <6> CFU/ml) de la suspension bactérienne afin de maintenir la concentration du nombre de cellules viables. 50pL de suspension bactérienne à 10 CFU/mL sont ainsi déposés dans chacune des cupules contenant 50pL d'essai de chaque solution antibactérienne, préparation à base d'acide transcinnamique ou d'antibiotique ou bien contenant 50pL de bouillon (témoins de croissance positifs). Dénombrement des solutions bactériennes d'essai immédiatement après l'inoculation. Les plaques de microdilution et les géloses de dénombrement sont incubées à 37°C pendant 18 + 2 heures. Résultats Contrôle de la viabilité du test Les témoins de croissance, la pureté et le nombre de cellules dans l'inoculum sont vérifiés : 14 - témoins de croissance positifs une turbidité est observée - témoins de croissance négatifs : aucune turbidité n'est observée - pureté : un seul type de colonies est observé sur les géloses de dénombrement - nombre de cellules . le nombre de colonies sur les géloses est compris entre 20 et 80 (valeur minimale). Objective and principle of the study Determine the MIC (Minimum Inhibitory Concentration) of cinnamic acid; versus antibiotics, antifungals and antivirals against resistant antigens and / or combination of antigens. Methodology and Standardized Protocol The method is based on determining the ability of microorganisms to produce visible growth in broth containing serial dilutions of the antimicrobial agent. Quality controls are carried out on at least two reference bacterial strains among the 6 strains proposed in the standard, and these two strains are tested under the same conditions as the bacterial solutions tested. Transcinnamic acid is obtained by chemical synthesis. The determination of the MIC of the transcinnamic acid is carried out by microdilution in broth, in accordance with the international standard NF EN ISO 20776-1 (April 2007). Laboratory and in vitro diagnostic testing systems In vitro susceptibility of infectious agents and performance evaluation of antibiogram devices - Part 1: Reference method for the determination of in vitro susceptibility to antimicrobial agents of the rapidly growing aerobic bacteria involved in infectious diseases. All manipulations and preparations are performed under the microbiological safety station, under sterile conditions. The transcinnamic acid preparation is carried out in physiological saline supplemented with 0.5% Tween (v / v) to facilitate solubilization. The preparation of the antibiotic solutions is carried out with the same solutions as those used for transcinnamic acid. Microdilution plates prepared for testing, test controls, positive growth controls, and negative growth controls should be inoculated within 30 minutes of normalization (10 <6> CFU / ml) of the bacterial suspension to to maintain the concentration of the number of viable cells. 50 μl of bacterial suspension at 10 CFU / ml are thus deposited in each well containing 50 μl of each antibacterial solution, preparation containing transcinnamic acid or antibiotic or containing 50 μl of broth (positive growth controls). Enumeration of bacterial test solutions immediately after inoculation. Microdilution plates and count plates are incubated at 37 ° C for 18 + 2 hours. Results Control of the viability of the test The growth controls, the purity and the number of cells in the inoculum are checked: 14 - positive growth controls a turbidity is observed - negative growth controls: no turbidity is observed - purity : Only one type of colony is observed on counts plates - number of cells. the number of colonies on the agar plates is between 20 and 80 (minimum value).
Le test n'est validé que si ces 4 points sont tous vérifiés, si le degré de croissance dans chaque cupule du contrôle qualité est comparable à celui des témoins de croissance positifs et si la CMI de l'antibiotique pour les bactéries témoins se trouve dans les plages de référence. The test is validated only if these 4 points are all checked, if the degree of growth in each quality control cup is comparable to that of the positive growth controls and if the MIC of the antibiotic for the control bacteria is in the reference ranges.
L'ensemble des résultats est reporté dans les tableaux 1 et 2. Le tableau 1 représente les résultats issus de la comparaison de la concentration minimale d'inhibition CMI nécessaire entre différents produits contre une souche de champignons. Le tableau 2 représente les résultats issus de la comparaison de la CMI nécessaire entre différents produits contre des souches de bactéries. Le tableau 1 montre les résultats pour trois souches de C. albicans . Les souches 1 et 2 sont dites classiques et la souche 3 est dite résistante. Ces résultats mettent clairement en évidence que l'acide transcinnamique est bien plus efficace que des antifongiques sur une telle souche résistante. En effet la CMI pour combattre la souche résistante est de 250 pour le Kétoconazole ou de 52 pour l'éconazole alors qu'elle n'est que de 0,013 pour le Kétoconazole et de 2 pour l'éconazole lorsqu'il s'agit d'une souche classique. 15 En revanche, la CMI nécessaire reste la même pour l'acide transcinnamique lorsqu'il s'agit de la souche classique ou bien de la souche résistante, cette dernière étant égale à 98. The overall results are reported in Tables 1 and 2. Table 1 represents the results obtained from the comparison of the minimum concentration of MIC inhibition required between different products against a strain of fungi. Table 2 shows the results from the comparison of the MIC required between different products against strains of bacteria. Table 1 shows the results for three strains of C. albicans. The strains 1 and 2 are said to be conventional and the strain 3 is said to be resistant. These results clearly demonstrate that transcinnamic acid is much more effective than antifungals on such a resistant strain. In fact, the MIC to fight the resistant strain is 250 for ketoconazole or 52 for econazole whereas it is only 0.013 for ketoconazole and 2 for econazole when it comes to a classic strain. On the other hand, the necessary MIC remains the same for transcinnamic acid in the case of the classical strain or the resistant strain, the latter being equal to 98.
Le tableau 2 montre les résultats pour des souches bactériennes, notamment E.coli et S.pyogenes. Il en résulte les mêmes conclusions que celles évoquées précédemment. En effet, la CMI nécessaire pour combattre une souche résistante de E.coli est multipliée par un facteur 16 pour l'amoxiciline et d'un facteur 8 pour la nitrofurantoine par rapport à celle nécessaire pour combattre une souche classique de E.coli alors que ce facteur n'est que de 2 pour l'acide transcinnamique. Il en est de même pour la souche S.pyogenes puisque la CMI nécessaire pour combattre une souche résistante est multipliée par un facteur 2 pour l'amoxiciline et d'un facteur 4 pour la nitrofurantoine par rapport à celle nécessaire pour combattre une souche classique, alors que la CMI reste inchangée pour l'acide transcinnamique. Table 2 shows the results for bacterial strains, in particular E.coli and S.pyogenes. This results in the same conclusions as those mentioned above. Indeed, the MIC necessary to fight a resistant strain of E. coli is multiplied by a factor of 16 for amoxicillin and by a factor of 8 for nitrofurantoin compared to that required to fight a classic strain of E. coli whereas this factor is only 2 for transcinnamic acid. It is the same for the S.pyogenes strain since the MIC needed to fight a resistant strain is multiplied by a factor 2 for amoxicillin and a factor of 4 for nitrofurantoin compared to that required to fight a classical strain, while the MIC remains unchanged for transcinnamic acid.
L'ensemble de ces résultats mettent clairement en évidence que l'utilisation d'acide transcinnamique permet de combattre certaines souches résistantes contre lesquelles les antibiotiques, antifongiques, antiviraux ou corticoïdes sont peu ou pas efficaces. Souches C.albicans C.albicans C.albicans Produits tests souche 1 souche 2 souche 3 CMI (mg/L) Trans- 49 49 49 Cinnamaldéhyde Kétoconazole 0,015 0,013 250 Econazole 2 2 52 Tableau 1 : Comparaison entre différents produits de la CMI nécessaire contre une souche de champignons Souches E.coli E.coli S.pyogenes S.pyogenes Produits tests souche 1 souche 2 souche 1 souche 2 CMI (mg/L) Trans- 98 196 98 98 Cinnamaldéhyde Amoxiciline 32 512 512 1024 Nitrofurantoine 16 128 512 2048 Tableau 2 : Comparaison entre différents produits de la CMI nécessaire contre des souches de bactéries5 All of these results clearly demonstrate that the use of transcinnamic acid makes it possible to combat certain resistant strains against which antibiotics, antifungals, antivirals or corticosteroids are little or not effective. C.albicans strains C.albicans C.albicans Test products strain 1 strain 2 strain 3 MIC (mg / L) Trans-49 49 49 Cinnamaldehyde Ketoconazole 0.015 0.013 250 Econazole 2 2 52 Table 1: Comparison between different products of the MIC required against strain of fungi Strains E. coli E.coli S.pyogenes S.pyogenes Test products strain 1 strain 2 strain 1 strain 2 MIC (mg / L) Trans-98 196 98 98 Cinnamaldehyde Amoxicillin 32 512 512 1024 Nitrofurantoin 16 128 512 2048 Table 2: Comparison between different MIC products required against strains of bacteria5
Claims (10)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1058971A FR2966732B1 (en) | 2010-10-29 | 2010-10-29 | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS |
| FR1354070A FR2989279B1 (en) | 2010-10-29 | 2013-05-02 | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1058971A FR2966732B1 (en) | 2010-10-29 | 2010-10-29 | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| FR2966732A1 true FR2966732A1 (en) | 2012-05-04 |
| FR2966732B1 FR2966732B1 (en) | 2013-06-28 |
Family
ID=43567947
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1058971A Expired - Fee Related FR2966732B1 (en) | 2010-10-29 | 2010-10-29 | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS |
| FR1354070A Expired - Fee Related FR2989279B1 (en) | 2010-10-29 | 2013-05-02 | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| FR1354070A Expired - Fee Related FR2989279B1 (en) | 2010-10-29 | 2013-05-02 | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS |
Country Status (1)
| Country | Link |
|---|---|
| FR (2) | FR2966732B1 (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10137410B2 (en) | 2014-11-04 | 2018-11-27 | IFP Energies Nouvelles | Method of deacidizing a gaseous effluent by an absorbent solution with vapor injection into the regenerated absorbent solution and device for implementing same |
| CN110538313A (en) * | 2019-09-27 | 2019-12-06 | 杭州玄盾科技有限公司 | Broad-spectrum malassezia-resistant natural product composition and application |
| CN110591962A (en) * | 2019-09-28 | 2019-12-20 | 华中农业大学 | Proteus mirabilis BSFLG-CIP5 derived from intestinal tracts of soldier flies and application thereof |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009153500A2 (en) * | 2008-05-28 | 2009-12-23 | Addevista | Plant-based compositions and uses |
| WO2010139805A1 (en) * | 2009-06-05 | 2010-12-09 | Septeos | Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections |
-
2010
- 2010-10-29 FR FR1058971A patent/FR2966732B1/en not_active Expired - Fee Related
-
2013
- 2013-05-02 FR FR1354070A patent/FR2989279B1/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009153500A2 (en) * | 2008-05-28 | 2009-12-23 | Addevista | Plant-based compositions and uses |
| WO2010139805A1 (en) * | 2009-06-05 | 2010-12-09 | Septeos | Composition including at least one trans-cinnamaldehyde and the use thereof in the treatment of bacterial infections, specifically in the treatment of nosocomial infections |
Non-Patent Citations (8)
| Title |
|---|
| AMALARADJOU M A R ET AL: "Antibiofilm Effect of Trans-Cinnamaldehyde on Uropathogenic Escherichia coli", JOURNAL OF UROLOGY, LIPPINCOTT WILLIAMS & WILKINS, BALTIMORE, MD, US, vol. 184, no. 1, 1 July 2010 (2010-07-01), pages 358 - 363, XP027475255, ISSN: 0022-5347, [retrieved on 20100520] * |
| CHANG S T ET AL: "Antibacterial activity of leaf essential oils and their constituents from Cinnamomum osmophloeum", JOURNAL OF ETHNOPHARMACOLOGY, ELSEVIER SCIENTIFIC PUBLISHERS LTD, IE, vol. 77, no. 1, 1 September 2001 (2001-09-01), pages 123 - 127, XP002555218, ISSN: 0378-8741, [retrieved on 20010726], DOI: DOI:10.1016/S0378-8741(01)00273-2 * |
| DE BILLERBECK V-G: "Essential oils and antibiotic-resistant bacteria", PHYTOTHÉRAPIE, SPRINGER-VERLAG, PARIS, FR, vol. 5, no. 5, 1 December 2007 (2007-12-01), pages 249 - 253, XP002555219, ISSN: 1624-8597, [retrieved on 20080104], DOI: DOI:10.1007/S10298-007-0265-Z * |
| EZZAOUIA S ET AL: "Investigation of essential oils to fight multiresistant bacteria in hygienicand therapeutic applications", INTERNATIONAL JOURNAL OF ESSENTIAL OIL THERAPEUTICS, CHURCHILL LIVINGSTONE, GB, vol. 1, no. 2, 1 January 2007 (2007-01-01), pages 51 - 55, XP009096945 * |
| LOOI ET AL: "Increased expression and hotspot mutations of the multidrug efflux transporter, CDR1 in azole-resistant Candida albicans isolates from vaginitis patients", FEMS MICROBIOLOGY LETTERS, BLACKWELL PUBLISHING, AMSTERDAM, NL, vol. 249, no. 2, 15 August 2005 (2005-08-15), pages 283 - 289, XP005010438, ISSN: 0378-1097, DOI: DOI:10.1016/J.FEMSLE.2005.06.036 * |
| PALANIAPPAN KAVITHA ET AL: "Use of natural antimicrobials to increase antibiotic susceptibility of drug resistant bacteria", INTERNATIONAL JOURNAL OF FOOD MICROBIOLOGY, vol. 140, no. 2-3, June 2010 (2010-06-01), pages 164 - 168, XP002624024, ISSN: 0168-1605 * |
| QUALE JOHN M ET AL: "In vitro activity of Cinnamomum zeylanicum against azole resistant and sensitive candida species and a pilot study of cinnamon for oral candidiasis", THE AMERICAN JOURNAL OF CHINESE MEDICINE, GARDEN CITY, NY, US, vol. 24, no. 2, 1 January 1996 (1996-01-01), pages 103 - 109, XP009117732, ISSN: 0192-415X, DOI: DOI:10.1142/S0192415X96000153 * |
| SHAHVERDI A R ET AL: "Trans-cinnamaldehyde from Cinnamomum zeylanicum bark essential oil reduces the clindamycin resistance of Clostridium difficile in vitro", JOURNAL OF FOOD SCIENCE, WILEY-BLACKWELL PUBLISHING, INC, US, vol. 72, no. 1, 1 January 2007 (2007-01-01), pages S055 - S058, XP002472467, ISSN: 0022-1147, DOI: DOI:10.1111/J.1750-3841.2006.00204.X * |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10137410B2 (en) | 2014-11-04 | 2018-11-27 | IFP Energies Nouvelles | Method of deacidizing a gaseous effluent by an absorbent solution with vapor injection into the regenerated absorbent solution and device for implementing same |
| CN110538313A (en) * | 2019-09-27 | 2019-12-06 | 杭州玄盾科技有限公司 | Broad-spectrum malassezia-resistant natural product composition and application |
| CN110538313B (en) * | 2019-09-27 | 2023-04-07 | 杭州玄盾科技有限公司 | Broad-spectrum malassezia-resistant natural product composition and application |
| CN110591962A (en) * | 2019-09-28 | 2019-12-20 | 华中农业大学 | Proteus mirabilis BSFLG-CIP5 derived from intestinal tracts of soldier flies and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| FR2989279B1 (en) | 2015-09-25 |
| FR2966732B1 (en) | 2013-06-28 |
| FR2989279A1 (en) | 2013-10-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6273065B1 (en) | Antifungal composition for the treatment of skin and nails | |
| JP7148994B2 (en) | Bisphosphosingel preparation and its use | |
| KR101846048B1 (en) | Antifungal compositions for the treatment of skin and nails | |
| EP3142675A1 (en) | Compositions containing boric acid and a mixture of lactobacillus | |
| US20210275476A1 (en) | Bactericidal and virucidal pharmaceutical composition | |
| EP1071421A1 (en) | Pharmaceutical imidazole combination for locally treating vulvovaginitis and vaginosis | |
| TW202206066A (en) | Pharmaceutical composition for preventing or treating tinea and use thereof | |
| EP2165704B1 (en) | Use of alverine for the treatment of cutaneous affections | |
| FR2989279A1 (en) | USE OF CINNAMIC ACID FOR PREVENTING OR TREATING INFECTIONS CAUSED BY A RESISTANT ANTIGEN OR A COMBINATION OF ANTIGENS | |
| CA2878496A1 (en) | Use of a myrtle extract as an anti-biofilm agent against p. acnes | |
| WO2022096605A1 (en) | Antiseptic composition | |
| BR112015032961B1 (en) | FORMULATION, AND, METHODS TO TREAT HUMAN OR ANIMAL WASTE AND TO ELIMINATE OR REDUCE MICROBIAL GROWTH IN A TREATMENT PLACE | |
| AU2018346361B2 (en) | Gluconic acid derivatives for use in the treatment and/or prevention of microbial infections | |
| CA1341359C (en) | Manufacturing process for a single-cell lifeform killing or growth inhibiting composition containing fluorine (f-) and lithium (li+) | |
| CA2973255A1 (en) | Methods of destroying and preventing bacterial and fungal biofilm by amino acid infusion | |
| US20180289656A1 (en) | Compositions and methods to treat urinary tract infections | |
| RU2659418C1 (en) | Antibacterial composition for delivery of gramicidin c to the locus of local inflammation, method for preparing antibacterial composition for delivering gramicidin c to locus of local inflammation, method for delivering gramicidin c to locus of local inflammation | |
| US20230330061A1 (en) | Antimicrobial compositions, pharmaceutical compositions and use thereof | |
| WO2020053509A1 (en) | Analogue compounds of squalamine and their medical use | |
| CA3219596A1 (en) | Compositions and uses therefor | |
| RU2295953C2 (en) | Hydrophilic and hydrophobic compositions for treatment infectious or viral diseases and method for their using | |
| WO2000024402A1 (en) | Use of antifungal agents for treating scleroses | |
| FR3143976A3 (en) | Pharmaceutical composition containing aqueous extract of the leaf bud of Musanga cecropioides and Alchornea cordifolia usable as an antibacterial and antifungal. | |
| CN118175994A (en) | Compositions and methods for treating biofilm disorders and infections | |
| FR3072279A1 (en) | USE OF CLOXACILLIN TO INHIBIT / PREVENT BIOFILM FORMATION |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PLFP | Fee payment |
Year of fee payment: 6 |
|
| PLFP | Fee payment |
Year of fee payment: 7 |
|
| ST | Notification of lapse |
Effective date: 20180629 |